News

Deal Announcements

Allakos Nets $32 Million First Venture Capital Funding

Wednesday, December 19, 2012 5:33:00 AM PDT | VentureDeal
   San Francisco, California  --  Biotechnology company Allakos has announced its Series A round of institutional and strategic venture capital investment.

Allakos is developing antibody-based therapeutics to treat immune responses in pathology, including allergic disease, inflammation and excess production of inflammatory cells.

Novo A/S led the round, which also included Alta Partners, RiverVest Venture Partners and Roche Venture Fund.

The company did not say how the funding proceeds would be used.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1